Evaluation of Dalia Solution For Depressed Patient

NANot yet recruitingINTERVENTIONAL
Enrollment

644

Participants

Timeline

Start Date

October 10, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions
Depression ChronicDepressedDepressed MoodDepression and Quality of LifeDepression Diagnosis
Interventions
DEVICE

Dalia Monitoring

All patients consulting psychiatrists and general practitioners in participating centers, meeting all eligibility criteria and agreeing to participate in the study, will be consecutively selected and randomized into one of the two groups. For iInterventional arm: Patients will benefit from Dalia telemonitoring, in addition to conventional care.

OTHER

Conventional healthcare

All patients consulting psychiatrists and general practitioners in participating centers, meeting all eligibility criteria and agreeing to participate in the study, will be consecutively selected and randomized into one of the two groups. For Control arm: Patients in this group will benefit from the conventional care pathway.

Trial Locations (1)

75005

Neurostim Luxembourg, Paris

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Dalia Care

INDUSTRY

NCT07211984 - Evaluation of Dalia Solution For Depressed Patient | Biotech Hunter | Biotech Hunter